How can we refine the prognostic stratification of triple-negative breast cancer?

Expert Rev Anticancer Ther. 2023 Jul-Dec;23(10):1045-1047. doi: 10.1080/14737140.2023.2248387. Epub 2023 Aug 17.

Authors

Federica Miglietta^{1

2}, Maria Vittoria Dieci^{1

2}

Affiliations

¹ Oncology Unit 2, Istituto Oncologico Veneto, IOV-IRCCS, (Via Gattamelata 64, Padova, Italy.
² Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.

PMID: 37581212
DOI: 10.1080/14737140.2023.2248387

No abstract available

Keywords: Triple-negative breast cancer; disease burden; prognosis; residual cancer burden; tumor infiltrating lymphocytes.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Disease-Free Survival
Humans
Prognosis
Receptor, ErbB-2
Triple Negative Breast Neoplasms* / diagnosis
Triple Negative Breast Neoplasms* / therapy

Substances

Receptor, ErbB-2